Puma Biotechnology Inc (NYSE:PBYI) SVP Sells $188,771.04 in Stock

Puma Biotechnology Inc (NYSE:PBYI) SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the transaction, the senior vice president now owns 27,246 shares of the company’s stock, valued at $2,574,202.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Richard Paul Bryce also recently made the following trade(s):

  • On Monday, July 3rd, Richard Paul Bryce sold 5,000 shares of Puma Biotechnology stock. The shares were sold at an average price of $87.10, for a total value of $435,500.00.

Puma Biotechnology Inc (NYSE PBYI) opened at 79.75 on Friday. Puma Biotechnology Inc has a 12-month low of $28.35 and a 12-month high of $98.85. The company’s 50 day moving average price is $87.66 and its 200-day moving average price is $58.07. The company’s market capitalization is $2.97 billion.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.32) by $0.78. Equities analysts forecast that Puma Biotechnology Inc will post ($8.62) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Puma Biotechnology Inc (NYSE:PBYI) SVP Sells $188,771.04 in Stock” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/puma-biotechnology-inc-nysepbyi-svp-richard-paul-bryce-sells-1998-shares-updated-updated-updated.html.

Institutional investors have recently modified their holdings of the company. Norges Bank acquired a new position in Puma Biotechnology during the fourth quarter worth about $7,693,000. Emerald Advisers Inc. PA acquired a new position in Puma Biotechnology during the first quarter worth about $14,110,000. BB Biotech AG increased its position in Puma Biotechnology by 1.5% in the first quarter. BB Biotech AG now owns 245,616 shares of the biopharmaceutical company’s stock worth $9,137,000 after buying an additional 3,625 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Puma Biotechnology during the first quarter worth about $7,682,000. Finally, American International Group Inc. increased its position in Puma Biotechnology by 19.2% in the first quarter. American International Group Inc. now owns 16,931 shares of the biopharmaceutical company’s stock worth $630,000 after buying an additional 2,733 shares in the last quarter. Institutional investors and hedge funds own 80.98% of the company’s stock.

A number of analysts have weighed in on the company. Stifel Nicolaus restated a “buy” rating and set a $110.00 target price (down previously from $118.00) on shares of Puma Biotechnology in a report on Thursday, August 10th. BidaskClub cut Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday. Citigroup Inc. upgraded Puma Biotechnology to a “buy” rating and set a $105.00 target price on the stock in a report on Sunday, May 28th. J P Morgan Chase & Co set a $105.00 price target on Puma Biotechnology and gave the company a “buy” rating in a research note on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $125.00 price target on shares of Puma Biotechnology in a research note on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. Puma Biotechnology currently has a consensus rating of “Buy” and a consensus price target of $109.56.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NYSE:PBYI)

What are top analysts saying about Puma Biotechnology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puma Biotechnology Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit